Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feireqing Granules for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections
NCT07206745Recruiting
- Sponsor
- Henan University of Chinese Medicine
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Feireqing Granules in multidrug-resistant gram-negative bacterial pneumonia (MDR-GNBP) (2 arms), sponsored by Henan University of Chinese Medicine. Primary endpoint: All-cause mortality at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
Feireqing Granules
03
Conditions
multidrug-resistant gram-negative bacterial pneumonia (MDR-GNBP)
Beyond the preview
Go deeper on NCT07206745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206745.